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Background
The use of the lipid-lowering agent niacin is hampered by
a frequent flush response which is largely mediated by
prostaglandin (PG) D2. Therefore, concomitant adminis-
tration of the D-type prostanoid (DP) receptor antagonist
laropiprant has been proposed to be a useful approach in
preventing niacin-induced flush. However, antagonizing
PGD2, which is a potent inhibitor of platelet aggregation,
might pose the risk of atherothrombotic events in cardio-
vascular disease. Therefore, we investigated the effects of
laropiorant on platelet function.
Methods
Platelet aggregation assays were performed ex vivo using a
platelet aggregation analyser (Aggregometer II). Blood
from healthy human donors was used to obtain platelet-
rich plasma. The expression of P-selectin and activation of
glycoprotein IIb/IIIa was examined using CD62P and
PAC1 antibodies, respectively, by direct flow cytometry.
In vitro thrombus formation was assessed by flowing whole
blood on collagen-coated Cellix biochips at −30 dyn/cm2
using the Mirus nanopump.
Results
In vitro treatment of platelets with laropiprant prevented
the inhibitory effects of PGD2 on platelet function, i.e.
platelet aggregation, P-selectin expression, activation of
glycoprotein IIb/IIIa and thrombus formation. In con-
trast, laropiprant did not prevent the inhibitory effects of
acetylsalicylic acid or niacin on thrombus formation. At
higher concentrations, laropiprant by itself attenuated
platelet activation induced by thromboxane (TP) and
E-type prostanoid (EP)-3 receptor stimulation, as demon-
strated in assays of platelet aggregation, P-selectin
expression, and activation of glycoprotein IIb/IIIa. Inhibi-
tion of platelet function exerted by EP4 or I-type prosta-
noid (IP) receptors was not affected by laropiprant.
Conclusions
These in vitro data suggest that niacin/laropiprant for
the treatment of dyslipidemias might have a beneficial
profile with respect to platelet function and thrombotic
events in vascular disease.
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